MRI as an outcome in multiple sclerosis clinical trials.

摘要

The results showed no correlation between clinical and MRI markers and were interpreted as an indication that MRI adds litde, if anything, to clinical measures. If confirmed, this should lead us to reconsider the use of MRI measures as surrogates of clinical endpoints in multiple sclerosis (MS) clinical trials. However, we believe that the study has important methodologic flaws, which limit the validity of the results and the consequent conclusions.